Technology Appraisal

The final stakeholder report from the telephone survey of provider and commissioner organisations which was undertaken to identify how NICE guidance is currently implemented across the North East and North Cumbria are now  published on the AHSN NENC website.

Follow up work is underway to understand the level of variation in the implementation of Technology Appraisals (TAs), identify further TAs for action, and identify how to take this work forward into 2015/16. With the support of the Pharmacy Lead for the Specialised Commissioning Team Cumbria, Northumberland, Tyne & Wear Area Team NHS England, the CfBCP has been able to identify the initial Technology Appraisals on which to focus. Work has begun to look at the regional variation in implementation for a range of drugs:

  • Natalizumab for multiple sclerosis – TA 127, August 2007
  • Fingolimod for multiple sclerosis – TA 254, April 2012
  • Pirfenidone for idiopathic pulmonary fibrosis – TA 282 April 2013
  • Azacitidine: TA218, March 2011, Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
  • Mifamurtide: TA235, October 2011, Mifamurtide for the treatment of osteosarcoma
  • Erlotinib: TA258, June 2012, Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer
  • Erlotinib: TA162, November 2008, Erlotinib for the treatment of non-small-cell lung cancer (i.e. 2nd line)

Data has now been analysed and the information is being shared with the relevant organisations to understand the reasons behind the apparent variation and identify any required action.

If you would like further information, please email Sue Shilling at NEQOS.